You are here

Mirabegron Works for Overactive Bladder, But Concerns About Liver, Heart Safety Remain

But the pill, already approved in Japan, was also tied to a higher rate of neoplasms, or tumors, urinary tract problems and hypersensitivity reactions, according to the FDA staff.

"The special safety concerns, especially the increases in blood pressure and pulse ... require additional consideration relevant to their potential negative public health effects," staff said in the documents.

The staff review comes ahead of a vote Thursday by an FDA advisory panel on whether to recommend approval of the drug. The FDA will make a final decision by June 29, taking into account the panel's recommendation.

Read the full article on Reuters.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels